Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology

PLoS One. 2013 Dec 31;8(12):e83922. doi: 10.1371/journal.pone.0083922. eCollection 2013.

Abstract

Increased availability of bioinformatics resources is creating opportunities for the application of network pharmacology to predict drug effects and toxicity resulting from multi-target interactions. Here we present a high-precision computational prediction approach that combines two elaborately built machine learning systems and multiple molecular docking tools to assess binding potentials of a test compound against proteins involved in a complex molecular network. One of the two machine learning systems is a re-scoring function to evaluate binding modes generated by docking tools. The second is a binding mode selection function to identify the most predictive binding mode. Results from a series of benchmark validations and a case study show that this approach surpasses the prediction reliability of other techniques and that it also identifies either primary or off-targets of kinase inhibitors. Integrating this approach with molecular network maps makes it possible to address drug safety issues by comprehensively investigating network-dependent effects of a drug or drug candidate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Artificial Intelligence*
  • Computational Biology*
  • Drug Discovery
  • Gene Regulatory Networks / drug effects*
  • Humans
  • Molecular Docking Simulation*
  • Protein Binding
  • Protein Interaction Maps / drug effects*
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinases / chemistry*
  • Protein Kinases / metabolism

Substances

  • Protein Kinase Inhibitors
  • Protein Kinases

Grants and funding

This work was supported by the HD-Physiology Project of the Japan Society for the Promotion of Science (JSPS) to the Okinawa Institute of Science and Technology Graduate University (OIST). This work, in part, has been carried out as research collaboration between the United States Food and Drug Administration (FDA) and the Systems Biology Institute (SBI) under Memorandum of Understanding Number 225-12-8000. Funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.